SIRT6 and neoplasm: By stimulating ERK1/2 activation and keeping low phospho-MAPK-p38 (pMAPK-p38) levels, Delta16HER2/SIRT6-OE tumor cells may acquire an initial proliferative advantage which later results in multiple tumor foci in vivo.